Abstracts tagged "histone acetylation and rheumatoid arthritis (RA)"

Abstract Number: 1448 • 2016 ACR/ARHP Annual Meeting
Therapeutic Role of a Novel Histone Deacetylase 6 Inhibitor, CKD-M808, in Rheumatoid Arthritis
Sehui Shon¹, Ji Soo Park², Daekwon Bae³, Nina Ha³, Young Il Choi³, Jin Kyun Park^1,2, Eun Young Lee², Eun Bong Lee² and Yeong Wook Song^1,2, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, The Republic of, Seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, Seoul, Korea, The Republic of, ³CKD Research Institute, 315-20 Dongbaekjukjeon-daero, Yongin-si, Gyeonggido, South Korea, Gyeonggido, South Korea
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory autoimmune disease whose etiology is unclear. Recently, upregulated HDAC (histone deacetylase) activity has been reported in peripheral…
Abstract Number: 2347 • 2014 ACR/ARHP Annual Meeting
Therapeutic Effect of a Novel Histone Deacetylase 6 Inhibitor, CKD-L, on Collagen Induced Arthritis and Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis
Bo Ram Oh¹, Hyojin Lim², Daekwon Bae², Nina Ha², Young il Choi², Hyun Jung Yoo^3,4, Jin Kyun Park³, Eun Young Lee⁵, Eun Bong Lee³ and Yeong Wook Song^3,4, ¹Division of Rheumatology, Department of Molecular Medicine and Biophamaceutical Sciences, BK 21 plus Graduate School of Convergence Science Technology, Colleage of Medicine, Seoul National University, Seoul, South Korea, ²Department of Pharmacology and Toxicology, CKD Research Institute, CKD Pharmaceutical Company, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ⁴Department of Molecular Medicine and Biophamaceutical Sciences, BK 21 plus Graduate School of Convergence Science Technology, Colleage of Medicine, Seoul National University, Seoul, South Korea, ⁵Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose Epigenetic regulation plays an important role in inflammatory arthritis, including rheumatoid arthritis (RA). Histone deacetylase inhibitor (HDACi) has been recently reported to have therapeutic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].